Buy Oncobiologics Stock | ONS Stock Price & Latest News | Public.com
ONS

Oncobiologics

    We couldn’t load this chart.

    Some stock charts might currently not be supported. To try again, please refresh this page.

    View Oncobiologics (ONS) stock trends here

    About ONS

    Outlook Therapeutics, Inc. is a clinical-stage biopharmaceutical company, which engages in the identification, development, manufacture, and commercialization of ONS-5010/LYTENAVA as the first FDA-approved ophthalmic formulation of bevacizumab-vikg for use in retinal in...Read more

    Buy any stock with any amount of money.

    Download the App
    Download the app

    Stats

    Market Cap$376,34M
    Volume
    Price-to-Earnings Ratio
    Dividend Rate
    Dividend Yield
    1 Year High$4.26
    1 Year Low$0.50
    Open
    High
    Low

    Buy any stock with any amount of money.

    Download the App
    Download the app